Novel Poly(L-lactide-co-ε-caprolactone) Matrices Obtained with the Use of Zr[Acac]₄ as Nontoxic Initiator for Long-Term Release of Immunosuppressive Drugs

Table 2

Microstructure of less random PLACL 75:25 matrices containing cyclosporine A or rapamycine (𝐹_LL, 𝐹_Cap: percentage molar content of lactidyl and caproyl unit; 𝑙_LL, 𝑙_Cap: the average length of lactidyl and caproyl sequences; 𝑅: randomization ratio) after 14, 35, 70, and 182 days of degradation.

Matrix	No.	days	𝐹LL	𝐹Cap	𝑙LL	𝑙Cap	R
Less random; PLACL 75 : 25	1	0	75	25	5.13	1.71	0.68
	2	14	75	25	5.17	1.72	0.68
	3	35	76	24	5.07	1.60	0.72
	4	70	92	8	—	—	—
	5	182	97	3	—	—	—
Less random; PLACL 75 : 25; + CyA	6	0	75	25	5.13	1.71	0.68
	7	14	75	25	5.64	1.65	0.67
	8	35	76	24	6.05	1.64	0.60
	9	70	76	24	6.04	1.60	0.60
	10	182	84	16	10.65	2.03	0.54
Less random; PLACL 75 : 25; + Rap	11	0	75	25	5.13	1.71	0.68
	12	14	75	25	5.87	1.71	0.65
	13	35	75	25	4.92	1.64	0.70
	14	70	75	25	4.80	1.60	0.73
	15	182	84	16	12.7	1.60	0.67